{
    "id": 21112,
    "fullName": "MAP2K1 I103N",
    "impact": "missense",
    "proteinEffect": "gain of function - predicted",
    "geneVariantDescriptions": [
        {
            "description": "MAP2K1 I103N lies within the protein kinase domain of the Map2k1 protein (UniProt.org). I103N is predicted to confer a gain of function on the Map2k1 protein as demonstrated by increased Map2k1 autophosphorylation in cell culture (PMID: 29753091) and is also associated with resistance to Mek inhibitors (PMID: 12370306, PMID: 19915144).",
            "references": [
                {
                    "id": 134,
                    "pubMedId": 19915144,
                    "title": "MEK1 mutations confer resistance to MEK and B-RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19915144"
                },
                {
                    "id": 11574,
                    "pubMedId": 29753091,
                    "title": "Increase in constitutively active MEK1 species by introduction of MEK1 mutations identified in cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29753091"
                },
                {
                    "id": 5157,
                    "pubMedId": 12370306,
                    "title": "Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12370306"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 5604,
        "geneSymbol": "MAP2K1",
        "terms": [
            "MAP2K1",
            "CFC3",
            "MAPKK1",
            "MEK1",
            "MKK1",
            "PRKMK1"
        ]
    },
    "variant": "I103N",
    "createDate": "04/14/2016",
    "updateDate": "09/11/2018",
    "referenceTranscriptCoordinates": {
        "id": 173412,
        "transcript": "NM_002755",
        "gDna": "chr15:g.66436762T>A",
        "cDna": "c.308T>A",
        "protein": "p.I103N",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 10426,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD6244) did not inhibit proliferation of melanoma cells expressing Map2k1 I103N (PMID: 19915144).",
            "molecularProfile": {
                "id": 21625,
                "profileName": "MAP2K1 I103N"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 134,
                    "pubMedId": 19915144,
                    "title": "MEK1 mutations confer resistance to MEK and B-RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19915144"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10427,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CI-1040 (PD184352) did not inhibit proliferation of melanoma cells expressing Map2k1 I103N (PMID: 19915144).",
            "molecularProfile": {
                "id": 21625,
                "profileName": "MAP2K1 I103N"
            },
            "therapy": {
                "id": 699,
                "therapyName": "CI-1040",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 134,
                    "pubMedId": 19915144,
                    "title": "MEK1 mutations confer resistance to MEK and B-RAF inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19915144"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 10425,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, CI-1040 (PD184352) partially inhibited kinase activity of Map2k1 I103N expressed in transformed human kidney cells (PMID: 12370306).",
            "molecularProfile": {
                "id": 21625,
                "profileName": "MAP2K1 I103N"
            },
            "therapy": {
                "id": 699,
                "therapyName": "CI-1040",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 5157,
                    "pubMedId": 12370306,
                    "title": "Identification of a novel mitogen-activated protein kinase kinase activation domain recognized by the inhibitor PD 184352.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/12370306"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5816,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, DEL-22379 inhibited growth of a melanoma cell line harboring BRAF V600E and expressing MAP2K1 I103N in culture (PMID: 26267534).",
            "molecularProfile": {
                "id": 21628,
                "profileName": "BRAF V600E MAP2K1 I103N"
            },
            "therapy": {
                "id": 3769,
                "therapyName": "DEL-22379",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 5811,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, over expression of MAPK21 I103N in melanoma cells harboring BRAF V600E resulted in insensitivity to growth inhibition by PD-0325901 in cell culture (PMID: 26267534).",
            "molecularProfile": {
                "id": 21628,
                "profileName": "BRAF V600E MAP2K1 I103N"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 4897,
                    "pubMedId": 26267534,
                    "title": "Small Molecule Inhibition of ERK Dimerization Prevents Tumorigenesis by RAS-ERK Pathway Oncogenes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26267534"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 21625,
            "profileName": "MAP2K1 I103N",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 21628,
            "profileName": "BRAF V600E MAP2K1 I103N",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 173412,
            "transcript": "NM_002755",
            "gDna": "chr15:g.66436762T>A",
            "cDna": "c.308T>A",
            "protein": "p.I103N",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 173413,
            "transcript": "XM_017022411",
            "gDna": "chr15:g.66436762T>A",
            "cDna": "c.308T>A",
            "protein": "p.I103N",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}